Search clinical trials for: ABT-335

Total 5653 results

Kineta Inc.
Wellcome Trust

Completed

Multiple Ascending Oral Dose 14-Day Trial of LHF-535 in Healthy Participants

Healthy

Australia
Aarhus University Hospital

Unknown

The Safety and Efficacy of a Novel HSP90 Inhibitor (CUDC-305) in the Treatment of Moderate to Severe Psoriasis.

Psoriasis Vulgaris

Denmark
Opsona Therapeutics Ltd.
M.D. Anderson Cancer Center; Montefiore Medical Center; New York Presbyterian... and other collaborators

Completed

A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States
Opsona Therapeutics Ltd.
M.D. Anderson Cancer Center; Montefiore Medical Center; New York Presbyterian... and other collaborators

Completed

Follow up Protocol to the Phase I/II Study of OPN-305 in Second-line or Third-line Lower Lower Risk Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States
Enanta Pharmaceuticals, Inc

Completed

Absorption, Metabolism and Excretion (AME) Study of [14C]EDP-305 in Healthy Male Subjects

NASH - Nonalcoholic Steatohepatitis

United States
Enanta Pharmaceuticals, Inc

Completed

A Study of EDP-305 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers

NASH

United States, Czechia, Slovakia
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of SAM-315 in Healthy Adults

Alzheimer Disease
Sosei

Completed

A Multicentre Trial to Determine the Efficacy and Safety of AD-337 in the Treatment of Fibromyalgia

Fibromyalgia

United Kingdom
The Deutsche Diabetes Forschungsgesellschaft e.V.
Algiax Pharmaceuticals GmbH

Recruiting

Effects of GABAA Receptor Modulation by AP-325 on Insulin Secretion in Patients With Type 2 Diabetes

Type2 Diabetes

Germany
Karyopharm Therapeutics Inc

Terminated

Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas (STARRS)

Squamous Cell Carcinoma

United States, Canada
AbbVie

Completed

A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis (MS)

United States, Canada
Centre Francois Baclesse
ARCAGY/ GINECO GROUP; French Cancer Research Hospital Program

Completed

A Study of ABT-263 as Single Agent in Women With Platinum Resistant/Refractory Recurrent Ovarian Cancer (MONAVI-1)

Platinum-resistant or Refractory Ovarian Cancer

France
AbbVie (prior sponsor, Abbott)

Completed

A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain (ELARIS EM-I)

Endometriosis
AbbVie

Completed

A Global Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain (ELARIS EM-II)

Endometriosis
AbbVie

Active, not recruiting

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic Dermatitis

Atopic Dermatitis

United States, Norway, Puerto Rico
Quigley Pharma, Inc.

Completed

Safety and Efficacy Study of QR-333 in Patient's With Symptomatic Diabetic Neuropathy

Diabetic Neuropathy

United States
University of Alabama at Birmingham

Completed

A Phase I Study of ABT 510 for Newly Diagnosed Glioblastoma Multiforme

Brain Tumor

United States
Abbott

Completed

Evaluate Safety and Efficacy of Paricalcitol in Reducing Serum Intact Parathyroid Hormone in Chronic Kidney Disease

Chronic Kidney Disease

China
University of Wisconsin, Milwaukee
National Institute of Mental Health (NIMH)

Completed

Testing a New Therapy for Trichotillomania

Trichotillomania

United States
Ascension Genesys Hospital

Unknown

Clostridial Infection and Oral Lavage -Improving Treatment Before Illness Becomes Severe (COLITIS)

Clostridium Difficile Colitis

United States
Sanofi Pasteur, a Sanofi Company

Completed

A Phase I, Randomized, Modified Single-blind, Active-controlled (Infants Only), Four-stage, Step-down, Comparative, Multi-center Study

Meningococcal Immunization
Chong Kun Dang Pharmaceutical

Not yet recruiting

Clinical Study to Investigate the PK Profiles and Safety of CKD-385 in Healthy Volunteers Under Fed Conditions

Cardiovascular Diseases

Korea, Republic of
Algiax Pharmaceuticals GmbH
FGK Clinical Research GmbH

Recruiting

AP-325 in Subjects With Peripheral Post-surgical Neuropathic Pain

Peripheral Post-surgical Neuropathic Pain

Czechia, Germany, Spain, Belgium, France
Frequency Therapeutics

Terminated

First in Human Safety Study of FX-345 in Adults With Sensorineural Hearing Loss

Hearing Loss, Sensorineural

United States
Aarhus University Hospital

Completed

A Double-blind Placebo-controlled Randomized Trial Evaluating the Efficacy and Safety of a Novel HSP90 Inhibitor (RGRN-305) in the Treatment of Moderate to Severe Hidradenitis Supppurativa.

Hidradenitis Suppurativa

Denmark
Karyopharm Therapeutics Inc

Completed

Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer

Hematological Malignancies

United States, Denmark, Canada
Karyopharm Therapeutics Inc

Terminated

Selinexor in Initial or Refractory and/or Relapsed Richter's Transformation (SIRRT)

Richter's Transformation

United States, Germany, United Kingdom, Spain, Poland
Beijing InnoCare Pharma Tech Co., Ltd.

Completed

A Phase I Randomized, Double-Blind, Placebo-Controlled, Parallel Group Clinical Study of ICP-332 in Healthy Subjects

Healthy Subjects

China
Takeda
Ovid Therapeutics Inc.

Completed

Study of TAK-935 as an Adjunctive Therapy in Participants With Developmental and/or Epileptic Encephalopathies

Developmental and/or Epileptic Encephalopathies

United States
Chong Kun Dang Pharmaceutical

Unknown

The Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-375

Type 2 Diabetes Mellitus
Morten Mau-Soerensen
Hospices Civils de Lyon; Gustave Roussy, Cancer Campus, Grand Paris; Institut... and other collaborators

Unknown

Selinexor in Patients With Advanced Thymoma and Thymic Carcinoma (TET-SEL)

Thymoma | Advanced Thymic Epithelial Tumour

Denmark, France
Amgen

Terminated

Phase I, Double-Blind,Placebo, MAD Study to Evaluate the Safety, Tolerability, PK, and PD of AMG 333 in Healthy Subjects and Migraine Subjects

Migraine

United States
Amgen

Completed

Single-Ascending Dose Study of AMG 333 in Healthy Subjects and Subjects With Migraines

Migraine

United States
Takeda

Completed

Safety and Efficacy Study of Once and Twice Daily Doses of MCC-135 in Subjects With Congestive Heart Failure.

Congestive Heart Failure

United States
Children's Hospital of Philadelphia
Food and Drug Administration (FDA)

Recruiting

Polyethylene Glycol Safety in Children

Children, Only | Polyethylene Glycols

United States
Mohammed Najeeb Al Hallak
National Cancer Institute (NCI)

Completed

Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer

Acinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Stage IV Pancreatic Cancer

United States
AbbVie

Completed

Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study (MAGELLAN-3)

Hepatitis C Virus Infection

United States, Australia, Canada, China, Germany, Korea, Republic of, New Zealand, Russian Federation, Spain, Sweden, Switzerland, United Kingdom
AbbVie

Completed

A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis (PsA) Who Have an Inadequate Response to Methotrexate (MTX)

Psoriatic Arthritis
Southern Europe New Drug Organization
Clinical Trial Unit Ente Ospedaliero Cantonale

Completed

Study to Investigate the Efficacy of Panitumumab in Platinum-resistant Advanced Head and Neck Squamous Cancer (S10PANI01)

Advanced Head and Neck Squamous Cancer
Yale University

Completed

A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL)

CTCL

United States
AbbVie (prior sponsor, Abbott)

Completed

Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United States, Australia, Israel, Poland, Ukraine
Abbott
Genentech, Inc.

Completed

Assess the Oral Bioavailability of a New ABT-263 Formulation in Healthy Female Subjects

Healthy Female Subjects

United States
King Faisal University
Mansoura University

Completed

Non-dependent Lung High Frequency Positive Pressure Ventilation (HFPPV) and Right Ventricular Function

Lung Diseases | Esophageal Diseases

Egypt
Enanta Pharmaceuticals, Inc

Recruiting

A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19 (SPRINT)

COVID-19

United States
Ligue Pulmonaire Neuchâteloise

Not yet recruiting

A Microphone for Monitoring Coughs (CoughMonit)

Chronic Obstructive Pulmonary Disease | Respiratory Disease

Switzerland
Takeda

Completed

A Study of Soticlestat Tablets in Healthy Adults

Healthy Volunteers

United States
Takeda

Active, not recruiting

A Study of Soticlestat in Adults and Children With Rare Epilepsies (Endymion 1)

Epilepsy | Dravet Syndrome (DS) | Lennox-Gastaut Syndrome (LGS)

United States, Canada, Australia, China, Israel, Poland, Spain, Portugal
Karyopharm Therapeutics Inc

Completed

A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma

Sarcoma

United States, Canada
Dana-Farber Cancer Institute
Karyopharm Therapeutics Inc; William Lawrence and Blanche Hughes Foundation

Active, not recruiting

Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML

Relapsed Acute Lymphoblastic Leukemia (ALL) | Refractory Acute Lymphoblastic Leukemia (ALL) | Relapsed Acute Myelogenous Leukemia (AML) | Refractory Acute Myelogenous Leukemia (AML) | Relapsed Mixed Lineage Leukemia | Refractory Mixed Lineage Leukemia | Relapsed Biphenotypic Leukemia | Refractory... and other conditions

United States
Calcilytix Therapeutics, Inc., a BridgeBio company

Completed

Safety, Tolerability, and Efficacy of Encaleret in Participants With Autosomal Dominant Hypocalcemia (ADH) Type 1

Autosomal Dominant Hypocalcemia (ADH)

United States

Search clinical trials for: ABT-335

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Panama

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations